Analysis of Influencing Factors of Unplanned Readmission in Patients With Acute Coronary Syndrome Within 30 Days After PCI
DOI:
https://doi.org/10.1532/hsf.4411Keywords:
Acute coronary syndrome, Percutaneous coronary intervention, Unplanned readmission, influence factorAbstract
Objective: The purpose of this study is to identify the influencing factors of unplanned readmission in patients with the acute coronary syndrome (ACS) within 30 days after percutaneous coronary intervention (PCI).
Methods: From November 1, 2018, to October 31, 2019, the clinical data of 1277 patients with acute coronary syndrome and percutaneous coronary intervention retrospectively were collected. After screening by exclusion and rejection criteria, a total of 936 patients finally entered the study. Patients were divided into the readmission group (57 cases) and the non-readmission group (879 cases), according to whether unplanned readmission occurred within 30 days after PCI. To analyze the influence of patients' age, past disease history, medication history, laboratory data, vascular diseases, and other factors on readmission and the clinical characteristics of readmission patients.
Results: Fifty-seven patients had unplanned readmission within 30 days, and the readmission rate was 6.09%. The clinical features of readmission patients are older age, longer hospitalization days, more emergency percutaneous coronary intervention, more patients with diabetes history, and more patients diagnosed with ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction. Logistic regression analysis revealed that smoking index, number of diseased vessels, ACEF score, diabetes, and PCI status were the influencing factors of unplanned readmission of ACS patients within 30 days after PCI.
Conclusion: Smoking index, number of diseased vessels, ACEF score, diabetes, and PCI status are the influencing factors of unplanned readmission within 30 days after percutaneous coronary intervention for patients with acute coronary syndrome.
References
arywani SB, Petzold M. 2016. Octogenarians died mainly of cardiovascular diseases five years after acute coronary syndrome[J]. Scandinavian Cardiovascular Journal. 50(5-6): 300-304.
Chow CK, Jolly S, Rao-Melacini P, et al. 2010. Association of diet, exercise, and smoking modification with risk of early cardiovascular events after acute coronary syndromes[J]. Circulation. 121(6): 750-758.
Critchley JA, Capewell S. 2003. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review[J]. Jama. 290(1): 86-97.
Epstein AJ, Daniel P, Feifei Y, et al. 2011. Coronary revascularization trends in the United States, 2001-2008[J]. Jama. 305(17): 1769.
Fanari Z, Elliott D, Russo CA, et al. 2017. Predicting readmission risk following percutaneous coronary intervention at the time of admission[J]. Cardiovascular Revascularization Medicine. 18(2): 100-104.
Hannan EL, Zhong Y, Krumholz H, et al. 2011. 30-day readmission for patients undergoing percutaneous coronary interventions in New York state[J]. JACC Cardiovascular Interventions. 4(12): 1335-1342.
Kwok CS, Hulme W, Olier I, et al. 2016. Review of early hospitalisation after percutaneous coronary intervention[J]. International Journal of Cardiology. 227(2017): 370-377.
Kwok CS, Rao SV, Potts JE, et al. 2018. Burden of 30-Day Readmissions After Percutaneous Coronary Intervention in 833,344 Patients in the United States: Predictors, Causes, and Cost: Insights From the Nationwide Readmission Database[J]. JACC Cardiovascular Interventions. 11(7): 665-674.
Lam L, Ahn HJ, Okajima K, et al. 2019. Gender Differences in the Rate of 30-Day Readmissions after Percutaneous Coronary Intervention for Acute Coronary Syndrome[J]. Womens Health Issues. 29(1): 17-22.
Mapanga RF, Joseph D, Symington B, et al. 2014. Detrimental effects of acute hyperglycaemia on the rat heart[J]. Acta Physiologica. 210(3): 546-564.
Moretti C, Meynet I, D'ascenzo F, et al. 2015. Sixty-day readmission rate after percutaneous coronary intervention: predictors and impact on long-term outcomes[J]. European Heart Journal Quality of Care and Clinical Outcomes. 1(2): 79-84.
Ranucci M, Castelvecchio S, Menicanti L, et al. 2009. Risk of assessing mortality risk in elective cardiac operations: age, creatinine, ejection fraction, and the law of parsimony[J]. Circulation, 2009, 119(24): 3053-3061.
Shengshou H, Runlin G, Lisheng L, et al. 2019. Summary of the 2018 Report on Cardiovascular Diseases in China [J]. Chinese Circulation Journal. 34(3): 209-220.
Spitzer E, Frei M, Zaugg S, et al. 2017. Rehospitalizations Following Primary Percutaneous Coronary Intervention in Patients With ST-Elevation Myocardial Infarction: Results From a Multi-Center Randomized Trial[J]. J Am Heart Assoc. 6(8): 1-18.
Tripathi A, Abbott J, Fonarow G, et al. 2017. Thirty-Day Readmission Rate and Costs After Percutaneous Coronary Intervention in the United States A National Readmission Database Analysis[J]. Circulation Cardiovascular Interventions. 69(11): 1093.
Ya W, Jifang C, Chongbin L, et al. 2020. Research progress on early readmission of patients after percutaneous coronary intervention [J]. Chinese Journal of Nursing. 55(10): 1598-1600.
Ya W, Wen-Jing S, Ze-Sheng J, et al. 2020. Serum albumin and the risk of contrast-induced acute kidney injury after percutaneous coronary intervention[J]. Reviews in cardiovascular medicine. 21(1): 139-145.
Yost GW, Puher SL, Graham J, et al. 2013. Readmission in the 30 Days After Percutaneous Coronary Intervention[J]. Jacc Cardiovascular Interventions. 6(3): 237-244.
Published
How to Cite
Issue
Section
Author Disclosure & Copyright Transfer Agreement
In order to publish the original work of another person(s), The Heart Surgery Forum® must receive an acknowledgment of the Author Agreement and Copyright Transfer Statement transferring to Forum Multimedia Publishing, L.L.C., a subsidiary of Carden Jennings Publishing Co., Ltd. the exclusive rights to print and distribute the author(s) work in all media forms. Failure to check Copyright Transfer agreement box below will delay publication of the manuscript.
A current form follows:
The author(s) hereby transfer(s), assign(s), or otherwise convey(s) all copyright ownership of the manuscript submitted to Forum Multimedia Publishing, LLC (Publisher). The copyright transfer covers the exclusive rights to reproduce and distribute the article and the material contained therein throughout the world in all languages and in all media of expression now known or later developed, including but not limited to reprints, photographic reproduction, microfilm, electronic data processing (including programming, storage, and transmission to other electronic data record(s), or any other reproductions of similar nature), and translations.
However, Publisher grants back to the author(s) the following:
- The right to make and distribute copies of all or part of this work for use of the author(s) in teaching;
- The right to use, after publication in The Heart Surgery Forum, all or part of the material from this work in a book by the author(s), or in a collection of work by the author(s);
- The royalty-free right to make copies of this work for internal distribution within the institution/company that employs the author(s) subject to the provisions below for a work-made-for-hire;
- The right to use figures and tables from this work, and up to 250 words of text, for any purpose;
- The right to make oral presentations of material from this work.
Publisher reserves the right to grant or refuse permission to third parties to republish all or part of the article or translations thereof. To republish, such third parties must obtain written permission from the Publisher. (This is in accordance with the Copyright Statute, United States Code, Title 17. Exception: If all authors were bona fide officers or employees of the U.S. Government at the time the paper was prepared, the work is a “work of the US Government” (prepared by an officer or employee of the US Government as part of official duties), and therefore is not subject to US copyright; such exception should be indicated on signature lines. If this work was prepared under US Government contract or grant, the US Government may reproduce, royalty-free, all or portions of this work and may authorize others to do so, for official US Government purposes only, if the US Government contract or grant so requires.
I have participated in the conception and design of this work and in the writing of the manuscript and take public responsibility for it. Neither this manuscript nor one with substantially similar content under my authorship has been published, has been submitted for publication elsewhere, or will be submitted for publication elsewhere while under consideration by The Heart Surgery Forum, except as described in an attachment. I have reviewed this manuscript (original version) and approve its submission. If I am listed above as corresponding author, I will provide all authors with information regarding this manuscript and will obtain their approval before submitting any revision. I attest to the validity, accuracy, and legitimacy of the content of the manuscript and understand that Publisher assumes no responsibility for the validity, accuracy, and legitimacy of its content. I warrant that this manuscript is original with me and that I have full power to make this Agreement. I warrant that it contains no matter that is libelous or otherwise unlawful or that invades individual privacy or infringes any copyright or other proprietary right. I agree to indemnify and hold Publisher harmless of and from any claim made against Publisher that relates to or arises out of the publication of the manuscript and agree that this indemnification shall include payment of all costs and expenses relating to the defense of any such claim, including all reasonable attorney’s fees.
I warrant that I have no financial interest in the drugs, devices, or procedures described in the manuscript (except as disclosed in the attached statement).
I state that the institutional Human Subjects Committee and/or the Ethics Committee approved the clinical protocol reported in this manuscript for the use of experimental techniques, drugs, or devices in human subjects and appropriate informed consent documents were utilized.
Furthermore, I state that any and all animals used for experimental purposes received humane care in USDA registered facilities in compliance with the “Principles of Laboratory Animal Care” formulated by the National Society for Medical Research and the “Guide for the Care and Use of Laboratory Animals” prepared by the Institute of Laboratory Animal Resources and published by the National Institutes of Health (NIH Publication No. 85-23, revised 1985).
